UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 86.02K | $43.82M | n/a | n/a |
| Q2 2026 | 159 | +4 | 28.20M | $15.29B | +8 | −3 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 5.33M | n/a | $1.53B | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (passive) | 4.45M | n/a | $1.28B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 2.17M | -2.8% | $622.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 2.12M | +0.6% | $608.92M | 0.8% | ▲ Add | 5 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.44M | -28.8% | $414.63M | 0.1% | ▼ Trim | 5 | SEC ↗ ×7 |
| 6 | AQR Capital Management ✦ | 1.27M | +40.1% | $362.88M | 0.3% | ▲ Add | 5 | SEC ↗ ×5 |
| 7 | Geode Capital Management ✦ (passive) | 1.20M | -1.9% | $344.26M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (passive) | 474.87K | +1.8% | $136.45M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Fidelity (FMR) ✦ | 424.24K | n/a | $121.91M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 10 | Arrowstreet Capital ✦ | 339.09K | -14.8% | $97.44M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 11 | Marshall Wace ✦ | 276.48K | +29.8% | $79.45M | 0.1% | ▲ Add | 2 | SEC ↗ ×3 |
| 12 | Bridgewater Associates ✦ | 195.12K | +0.7% | $56.07M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 141.01K | +289.7% | $40.52M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 114.50K | -39.6% | $32.90M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 15 | Gotham Asset Management ✦ | 89.40K | +0.1% | $25.69M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 16 | Millennium Management ✦ | 77.06K | +1809.9% | $22.14M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 21.61K | -28.6% | $6.21M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 18 | Fisher Asset Management ✦ | 18.59K | 0.0% | $5.34M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 8.80K | +477.1% | $2.53M | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 844 holders, 41.22M shares, $23.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 200 sh · $110,143
Officer, Director · 2.17K sh · $1.19M
Officer, Director · 281 sh · $151,874
Officer · 268 sh · $145,160
Officer, Director · 456 sh · $247,462
Officer, Director · 601 sh · $328,713
Officer, Director · 371 sh · $201,599
Officer · 1.98K sh · $1.08M
Officer · 791 sh · $430,975
Officer, Director · 825 sh · $450,347
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology